enzalutamide

an antineoplastic agent

Also Known As:

4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)benzamide; 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-benzamide; HC 1119; HC-1119; MDV 3100; MDV-3100; MDV3100; Xtandi; enzalutamide D3

Networked: 1866 relevant articles (242 outcomes, 439 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Antonarakis, Emmanuel S: 46 articles (01/2022 - 01/2013)
2.	Armstrong, Andrew J: 42 articles (09/2022 - 03/2012)
3.	Saad, Fred: 40 articles (03/2022 - 09/2012)
4.	Fizazi, Karim: 36 articles (03/2022 - 09/2012)
5.	Beer, Tomasz M: 35 articles (01/2022 - 05/2009)
6.	Sternberg, Cora N: 33 articles (03/2022 - 05/2012)
7.	De Giorgi, Ugo: 31 articles (04/2022 - 12/2014)
8.	de Bono, Johann S: 30 articles (03/2022 - 12/2009)
9.	Tombal, Bertrand: 29 articles (01/2022 - 05/2014)
10.	Scher, Howard I: 26 articles (03/2022 - 05/2009)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 01/01/2018 - "Combination studies of KV-37 with enzalutamide reveal a very high degree of synergistic drug interaction that induces significant reduction in prostate cancer cell viability via apoptosis, resulting in >200-fold potentiation of enzalutamide action in drug-resistant 22Rv1 cells. " 01/01/2021 - "Moreover, the addition of a CDK1 inhibitor or knockdown of CDK1 significantly improved the efficacy of enzalutamide on prostate cancer cells. " 10/01/2022 - "This study suggests that enzalutamide may be combined with the STAT3 inhibitor GPB730 in order to enhance the efficacy of enzalutamide, offering a new therapeutic approach in advanced prostate cancer." 12/01/2019 - "Enzalutamide (Enza) is an effective treatment for metastatic castrate-resistant prostate cancer (mCPRC). " 01/01/2014 - "Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial."
2.	Neoplasms (Cancer) 01/01/2023 - "Furthermore, the deletion of RhoA dramatically increased the efficacy of enzalutamide in inhibiting 22RV1-derived xenograft tumor growth. " 10/02/2023 - "In xenograft studies, MPC309 produced significantly greater tumor suppression than enzalutamide. " 01/01/2023 - "Co-administration of YIV-818-A and enzalutamide led to a significant reduction of 22RV1 tumor growth in vivo. " 01/01/2022 - "Compared with AS, odds of a negative biopsy result were 3.5 times higher; there was a significant reduction in the percentage of cancer-positive cores and the odds of a secondary rise in serum PSA levels at 1 year with treatment with enzalutamide; no significant difference was observed at 2 years. " 10/01/2020 - "Inhibition of KDM4B significantly inhibited prostate tumor cell growth in xenografts, and improved enzalutamide treatments through suppression of c-Myc. "
3.	Neoplasm Metastasis (Metastasis) 06/01/2017 - "The NEB scored enzalutamide 4 (very effective) for efficacy, 4 (occasionally toxic) for safety, and 2 (expensive) for affordability in the no visceral metastases block. " 01/01/2017 - "Enzalutamide-treated patients who had lung metastases (n = 104) had improved median OS (HR, 0.848; 95% CI, 0.510-1.410), a substantially reduced risk of radiographic progression (HR, 0.386; 95% CI, 0.259-0.577), improved 12-month OS (65.1% vs 55.3%) and rPFS (30.9% vs 8.2%) rates, increased time to PSA progression (HR, 0.358; 95% CI, 0.204-0.627), and a better PSA response rate (52.1% vs 4.9%) compared with those who received placebo. " 01/01/2017 - "In patients who had liver metastases (n = 92), enzalutamide was associated with a lower risk of radiographic progression (hazard ratio [HR], 0.645; 95% confidence interval [CI], 0.413-1.008), improved 12-month OS (37.7% vs 20.6%) and radiographic progression-free survival (rPFS) (11.6% vs 3.0%) rates, and higher PSA response rates (35.1% vs 4.8%) compared with placebo. " 08/01/2023 - "Treatment with enzalutamide plus ADT improved survival and other outcomes over ADT alone, whether patients had few or many metastases." 10/01/2017 - "In patients with liver metastases, enzalutamide was associated with an improvement in rPFS (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.22-0.90) but not OS (HR, 1.04; 95% CI, 0.57-1.87). "
4.	Disease Progression 10/01/2022 - "Enzalutamide was associated with improved deterioration-free survival for OHQL, physical function, and cognitive function because delays in disease progression outweighed early deteriorations in these aspects of HRQL." 12/01/2021 - "Patients who had developed disease progression on or were eligible for enzalutamide were enrolled in the study. " 10/17/2023 - "These data highlight the dynamic nature of NaF PET in mCRPC patients treated with enzalutamide, where not all new findings were ultimately related to disease progression. " 01/01/2021 - "PC samples spanning one patient's clinical course: diagnostic biopsies, pre- or post-enzalutamide metastatic biopsies, and rapid autopsy samples including a patient-derived xenograft (PDX) were analyzed by targeted exome sequencing followed by phylogenetic analysis. " 02/01/2020 - "Thereafter, he has been treated with enzalutamide for 3 years without clinical progression of either disease."
5.	Fatigue 01/01/2022 - "In all trials, patients reported a small increase in fatigue for the first 13-17 weeks after starting enzalutamide or placebo, with slightly greater fatigue with enzalutamide in all studies except AFFIRM, but fatigue stabilized or improved thereafter. " 01/01/2019 - "General fatigue after introduction of enzalutamide mainly consisted of physical fatigue, and improved in two of the three cases included in this study. " 11/01/2019 - "This is the first report of a CFS-based evaluation of the improvement in general fatigue caused by enzalutamide by switching to nighttime treatment." 01/01/2022 - "This study assesses the impact enzalutamide has on patient-reported fatigue ("fatigue") by using patient-reported outcomes from four pivotal, placebo-controlled trials of enzalutamide (ARCHES (NCT02677896), PROSPER (NCT02003924), PREVAIL (NCT01212991), and AFFIRM (NCT00974311)). " 10/01/2018 - "In the real-life setting, there was a higher incidence of enzalutamide-related fatigue than reported in the trials. "

Related Drugs and Biologics

1.	abiraterone
2.	Docetaxel (Taxotere)
3.	Androgens
4.	Androgen Receptors (Androgen Receptor)
5.	Abiraterone Acetate
6.	apalutamide
7.	Hormones (Hormone)
8.	cabazitaxel
9.	darolutamide
10.	sipuleucel-T (APC8015)

Related Therapies and Procedures

1.	Castration
2.	Therapeutics
3.	Drug Therapy (Chemotherapy)
4.	Immunotherapy
5.	Radiotherapy